{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T19:36:50Z","timestamp":1772912210418,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations. Thus, there are concerns about systemic complications, in these premature infants who are developing vital organ systems. This study is to determine whether a low dosage (0.15\u2009mg\/0.015\u2009mL) of IVC is effective in the treatment of Zone II Stage 2\/3\u2009+\u2009ROP. A total of 38 eyes of 20 infants were analyzed retrospectively. We identified treatment effectiveness as complete regression of retinopathy and retinal vascularisation to zone III. The mean gestational age (GA), postmenstrual age (PMA) at treatment and birth weights (BW) were 28.6\u2009\u00b1\u20092.2 weeks, 39.3\u2009\u00b1\u20093.0 weeks and 1297.5\u2009\u00b1\u2009429.2\u2009g respectively. Primary effectiveness (react to IVC 0.15\u2009mg alone) was found in 32\/38 eyes (84.2%). Secondary effectiveness (a second IVC was required) was found in 6\/38 eyes (15.8%). Follow-up continued until 90 weeks\u2019 postmenstrual age and showed no recurrences of plus disease or neovascularization. The study suggests 0.15\u2009mg IVC is effective for Zone II Stage 2\/3\u2009+\u2009ROP, and there is no adverse ocular outcomes during the follow-up period.<\/jats:p>","DOI":"10.1038\/s41598-018-28987-6","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T13:23:42Z","timestamp":1531229022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity"],"prefix":"10.1038","volume":"8","author":[{"given":"Yong","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Linghu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"28987_CR1","doi-asserted-by":"crossref","unstructured":"The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 123, 991\u20139 (2005).","DOI":"10.1001\/archopht.123.7.991"},{"key":"28987_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner, H. A., Kennedy, K. A. & Chuang, A. Z. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 364, 603\u201315 (2011).","journal-title":"N Engl J Med."},{"key":"28987_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","volume":"42","author":"M Gunay","year":"2016","unstructured":"Gunay, M., Sukgen, E. A., Celik, G. & Kocluk, Y. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey. Curr Eye Res. 42, 462\u2013469 (2016).","journal-title":"Curr Eye Res."},{"key":"28987_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/bjophthalmol-2016-308828","volume":"101","author":"Y Kandasamy","year":"2017","unstructured":"Kandasamy, Y., Hartley, L., Rudd, D. & Smith, R. The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review. Br J Ophthalmol. 101, 21\u201324 (2017).","journal-title":"Br J Ophthalmol."},{"key":"28987_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nm721","volume":"8","author":"V Compernolle","year":"2002","unstructured":"Compernolle, V. et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med. 8, 702\u201310 (2002).","journal-title":"Nat Med."},{"key":"28987_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.expneurol.2004.01.022","volume":"187","author":"JM Rosenstein","year":"2004","unstructured":"Rosenstein, J. M. & Krum, J. M. New roles for VEGF in nervous tissue\u2013beyond blood vessels. Exp Neurol. 187, 246\u201353 (2004).","journal-title":"Exp Neurol."},{"key":"28987_CR7","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1167\/iovs.08-2584","volume":"49","author":"LE Smith","year":"2008","unstructured":"Smith, L. E. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 49, 5177\u201382 (2008).","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"28987_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/eye.2009.63","volume":"24","author":"CS Yang","year":"2010","unstructured":"Yang, C. S. et al. Long-term visual outcomes of laser-treated threshold retinopathy of prematurity: a study of refractive status at 7 years. Eye (Lond). 24, 14\u201320 (2010).","journal-title":"Eye (Lond)."},{"key":"28987_CR9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3928\/01913913-20131112-02","volume":"51","author":"SD Nicoara","year":"2014","unstructured":"Nicoara, S. D., Cristian, C., Irimescu, I., Stefanut, A. C. & Zaharie, G. Diode laser photocoagulation for retinopathy of prematurity: outcomes after 7 years of treatment. J Pediatr Ophthalmol Strabismus. 51, 39\u201345 (2014).","journal-title":"J Pediatr Ophthalmol Strabismus."},{"key":"28987_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ophtha.2016.10.032","volume":"124","author":"J Feng","year":"2017","unstructured":"Feng, J. et al. Efficacy of Primary Intravitreal Ranibizumab for Retinopathy of Prematurity in China. Ophthalmology. 124, 408\u20139 (2017).","journal-title":"Ophthalmology."},{"issue":"15","key":"28987_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0001-7","volume":"8","author":"MN Menke","year":"2015","unstructured":"Menke, M. N. et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol. 8(15), 20 (2015).","journal-title":"BMC Ophthalmol."},{"key":"28987_CR12","doi-asserted-by":"crossref","unstructured":"Jin, E., Yin, H., Li, X. & Zhao, M. Short-Term Outcomes after Intravitreal Injections of Conbercept Versus Ranibizumab for the Treatment of Retinopathy of Prematurity. Retina. 7 (2017).","DOI":"10.1097\/IAE.0000000000001763"},{"key":"28987_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato, T. et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 153, 327\u201333 e1 (2012).","journal-title":"Am J Ophthalmol."},{"key":"28987_CR14","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster, R. et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 91, e74\u20135 (2013).","journal-title":"Acta Ophthalmol."},{"key":"28987_CR15","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","volume":"10","author":"L Pertl","year":"2015","unstructured":"Pertl, L. et al. A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. PLoS One. 10, e0129383 (2015).","journal-title":"PLoS One."},{"issue":"Suppl 12","key":"28987_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/IAE.0000000000000399","volume":"34","author":"RL Avery","year":"2014","unstructured":"Avery, R. L. et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 34(Suppl 12), S1\u2013S18 (2014).","journal-title":"Retina."},{"key":"28987_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.5935\/0004-2749.20160080","volume":"79","author":"OM Ceylan","year":"2016","unstructured":"Ceylan, O. M., Dikci, S., Genc, O. & Yilmaz, T. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol. 79, 279 (2016).","journal-title":"Arq Bras Oftalmol."},{"key":"28987_CR18","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1080\/02713683.2017.1285943","volume":"42","author":"F Li","year":"2017","unstructured":"Li, F., Sun, M., Guo, J., Ma, A. & Zhao, B. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion. Curr Eye Res. 42, 1174\u20138 (2017).","journal-title":"Curr Eye Res."},{"key":"28987_CR19","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","volume":"121","author":"X Li","year":"2014","unstructured":"Li, X. et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 121, 1740\u20137 (2014).","journal-title":"Ophthalmology."},{"key":"28987_CR20","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1167\/iovs.09-4140","volume":"51","author":"T Miyake","year":"2010","unstructured":"Miyake, T. et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 51, 1606\u20138 (2010).","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"28987_CR21","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1167\/iovs.09-4425","volume":"51","author":"WC Wu","year":"2010","unstructured":"Wu, W. C. et al. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci. 51, 3701\u20138 (2010).","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"28987_CR22","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri, S. J. et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 114, 2179\u201382 (2007).","journal-title":"Ophthalmology."},{"key":"28987_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","volume":"133","author":"WC Wu","year":"2015","unstructured":"Wu, W. C. et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 133, 391\u20137 (2015).","journal-title":"JAMA Ophthalmol."},{"key":"28987_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jaapos.2016.09.012","volume":"20","author":"A Khodabande","year":"2016","unstructured":"Khodabande, A., Niyousha, M. R. & Roohipoor, R. A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity. J AAPOS. 20, 490\u20132 (2016).","journal-title":"J AAPOS."},{"key":"28987_CR25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/bjophthalmol-2017-310408","volume":"102","author":"RJ Hillier","year":"2018","unstructured":"Hillier, R. J., Connor, A. J. & Shafiq, A. E. Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series. Br J Ophthalmol. 102, 260\u2013264 (2018).","journal-title":"Br J Ophthalmol."},{"key":"28987_CR26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","volume":"135","author":"DK Wallace","year":"2017","unstructured":"Wallace, D. K. et al. Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmol. 135, 654\u20136 (2017).","journal-title":"JAMA Ophthalmol."},{"key":"28987_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jcjo.2017.02.012","volume":"52","author":"AL Ells","year":"2017","unstructured":"Ells, A. L., Wesolosky, J. D., Ingram, A. D., Mitchell, P. C. & Platt, A. S. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity. Can J Ophthalmol. 52, 468\u201374 (2017).","journal-title":"Can J Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28987-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28987-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28987-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:39:59Z","timestamp":1671608399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28987-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["28987"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-28987-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"13 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10732"}}